SCHEMBL22615322

SCHEMBL22615322

CC(NC(=O)c1[nH]nc2c1CN(C(=O)c1cc3ccccn3c1)CC2)C1COC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ IMPDH2 P12268 1/20 0.33
▸ PRLHR P49683 4/20 0.32
▸ MTHFD2 P13995 3/20 0.32
▸ RIPK1 Q13546 1/20 0.31
▸ ITGB2 P05107 2/20 0.31
▸ ICAM1 P05362 2/20 0.31
▸ ITGAL P20701 2/20 0.31
▸ NAMPT P43490 1/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ PDE10A Q9Y233 2/20 0.31
▸ ATM Q13315 1/20 0.31
▸ PDE2A O00408 1/20 0.31
▸ SLC28A2 O43868 1/20 0.31
▸ PDE5A O76074 1/20 0.31
▸ PDE6A P16499 1/20 0.31
▸ PDE4A P27815 1/20 0.31
▸ PDE7A Q13946 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22615213 0.87 GSK3B (0.37) CHRNA7NPC1RAB9APRLHRMTHFD2
SCHEMBL22615211 0.87 GSK3B (0.37) CHRNA7NPC1RAB9APRLHRMTHFD2
SCHEMBL22615328 0.87 GSK3B (0.37) CHRNA7NPC1RAB9APRLHRMTHFD2
SCHEMBL22615579 0.82 MTHFD2 (0.40) CHRNA7MTHFD2PTGS1
SCHEMBL22615482 0.82 NAMPT (0.38) CHRNA7IMPDH2MTHFD2NAMPTPDE10A
SCHEMBL22615399 0.81 CHRNA7 (0.35) CHRNA7PRLHRMTHFD2
SCHEMBL22615319 0.81 NAMPT (0.39) CHRNA7NAMPT
SCHEMBL22615366 0.80 NAMPT (0.41) NAMPT
SCHEMBL22615401 0.79 AURKA (0.39) MTHFD2RIPK1
SCHEMBL22615335 0.79 DDR1 (0.34) CHRNA7MTHFD2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220227789-A1 NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2022-07-21 — — US disclosed
EP-3962913-A1 NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AiCuris GmbH & Co. KG (DE) 2022-03-09 — — EP disclosed
WO-2020221824-A1 NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2020-11-05 — — WO disclosed
WO-2020221824-A1 NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2020-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220227789-A1 NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) HCCS, CDK2, BRD4 CHRNA7 4715/4885NPC1 2412/4885RAB9A 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback